BEONE MEDICINES LTD (ONC)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
Research Workspace
Put ONC beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 34% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 20%.
View QualityManagement screens strong on capital allocation, margins.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskHealthy across the board
BeOne Medicines relies on Brukinsa's global expansion to justify its valuation. Revenue grew 30% year over year in the second quarter. The company beat its earnings estimate by 174% in that period. It trades at 67 times earnings versus a 21 times peer median. The price reflects less growth than our forecast suggests. A guidance cut after a recent raise would hurt credibility. Our model puts the next-quarter miss probability near 30%. Peer multiples imply a price about 5% below where it trades. This read is provisional.
Trailing returns as of 2026-11-04. ONC is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 27 analysts currently covering ONC (as of Nov 2026).
Based on 6 Wall Street analysts offering 12-month price targets for ONC in the last 4 months.
Continue this research
Compare ONC with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ONC Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 4 valuation methods, at three horizons. As of 2026-11-05. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put ONC next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Increase GAAP operating income to $1.0-$1.1 billion in 2026
Earnings beat supports operating income trajectory.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $377.78
The last 12 months of price, then the range of analyst 12-month targets from today’s $377.78.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.

Advances: Expand BRUKINSA's global market presence
Accelerates label expansion, supporting global market growth.

Advances: Expand BRUKINSA's global market presence
Tariff exemption supports global market expansion for BRUKINSA.

Advances: Advance sonrotoclax (BEQALZI) clinical and regulatory milestones
FDA approval supports sonrotoclax clinical and regulatory milestones.

Advances: Expand BRUKINSA's global market presence
Revenue surge supports global market expansion for BRUKINSA.

Phase 3 programs enhance growth potential.
Improved survival data supports market expansion.